Newsfiscal.ai
Anixa Biosciences Completes Dosing of Fifth Cohort in Ovarian Cancer CAR-T Trial
· Published
Article summary
Anixa Biosciences has finished dosing the fifth cohort in its Phase 1 clinical trial evaluating a novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…